PharmaShots | Incisive News in 3 Shots

Subscribe Now

nuvation bio

Nuvation Bio Reports the US FDA’s NDA Acceptance of Taletrectinib with Priority Review to Treat Advanced ROS1+ NSCLC

Nuvation Bio Reports the US FDA’s NDA Acceptance of Taletrectinib with Priority Review to Treat Advanced ROS1+ NSCLC

December 25, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us